One man's trash may be another man's treasure, but dumpster diving when investing carries risks. You have to wade through a ...

Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of ...

With macroeconomic uncertainty swirling, Bank of America analyst Anthony Cassamassino warns that a worst-case scenario could ...

The results exceeded Wall Street targets and pushed the U.S. drugmaker's shares up 11% in premarket trading, while dragging ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

PARIS – Amid the luxury slowdown, Hermès International showed continued strength with sales in the first quarter up 7 percent ...

Eli Lilly shares slid 8.2% last month thanks to tariff tremors and Medicare’s snub of pricey weight-loss drugs. The company’s ...

The maker of factory robots, electric motors and drives said its operational earnings before interest, tax and amortisation ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

So far this year, Pfizer shares have dropped 17.4%, while Novo Nordisk's stock has tumbled 24% and Lilly shares have slipped 3.2%. The SPDR S&P Pharmaceuticals ETF XPH has shed 12.1% year to date and ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity after venturing into the biggest and ...

Pfizer has discontinued its experimental weight-loss pill danuglipron after a trial patient experienced potential ...